Display options
Filter resources
Text Availability
Article type
Publication date
Showing 1 to 12 of 58347 entries
Sorted by: Best Match Show Resources per page
Growth factors and other targets for rational application as intervention agents.

Advances in experimental medicine and biology

Mulshine JL, Birrer M, Treston AM, Scott F, Quinn K, Avis I, Cuttitta F.
PMID: 1442286
Adv Exp Med Biol. 1992;320:81-8. doi: 10.1007/978-1-4615-3468-6_11.

No abstract available.

A rational design of synthetic peptide vaccine with a built-in adjuvant. A modular approach for unambiguity.

International journal of peptide and protein research

Defoort JP, Nardelli B, Huang W, Tam JP.
PMID: 1478779
Int J Pept Protein Res. 1992 Sep-Oct;40(3):214-21. doi: 10.1111/j.1399-3011.1992.tb00294.x.

We describe a peptide vaccine model containing a built-in adjuvant. This model used a multiple antigen peptide system (MAPS) to amplify peptide antigens and a lipoamino acid, tripalmitoyl glyceryl cysteine (P3C), as a built-in adjuvant. An 18-residue peptide antigen...

Physiological principles for the design of hepatic contrast agents.

European journal of radiology

Stark DD.
PMID: 1314179
Eur J Radiol. 1992 Mar-Apr;14(2):124-7. doi: 10.1016/0720-048x(92)90225-x.

No abstract available.

Design and synthesis of heterofunctional V1a-selective vasopressin receptor ligands with lysine at position 9.

Journal of molecular endocrinology

Howl J, New DC, Wheatley M.
PMID: 1418383
J Mol Endocrinol. 1992 Oct;9(2):123-9. doi: 10.1677/jme.0.0090123.

A peptide analogue of [8-arginine]vasopressin (AVP) with Lys substituted for Gly at position 9 ([d(CH2)5Tyr(Me)2LysNH2(9)]AVP; ALVP) has been synthesized as a precursor for the production of heterofunctional vasopressin receptor ligands. Three heterofunctional ligands have been prepared by attaching biotin...

[A new principle for the design of immunotherapeutic compounds of directed action. Physiologically active substances reversibly screened with target-recognizing macromolecules].

Doklady Akademii nauk SSSR

Alakhov VIu, Arzhakov SA, Vasilenko OV, Voloshchuk SG, Glazkova-Stepanenko IS.
PMID: 3266934
Dokl Akad Nauk SSSR. 1988;303(6):1494-7.

No abstract available.

Application of neural networks: quantitative structure-activity relationships of the derivatives of 2,4-diamino-5-(substituted-benzyl)pyrimidines as DHFR inhibitors.

Journal of medicinal chemistry

So SS, Richards WG.
PMID: 1507206
J Med Chem. 1992 Aug 21;35(17):3201-7. doi: 10.1021/jm00095a016.

A comparative study of quantitative structure-activity relationships involving diaminopyrimidines as DHFR inhibitors using regression analysis and the neural-network approach suggests that the neural network can outperform traditional methods. The technique permits the highlighting the functional form of those parameters...

Bioanalytical data in decision making: discovery and development.

Xenobiotica; the fate of foreign compounds in biological systems

Smith DA, Beaumont K, Cussans NJ, Humphrey MJ, Jezequel SG, Rance DJ, Stopher DA, Walker DK.
PMID: 1441610
Xenobiotica. 1992 Sep-Oct;22(9):1195-205. doi: 10.3109/00498259209051873.

1. Bioanalysis is traditionally associated with the development phase of drugs; its use in discovery programmes is often ignored but can have a major impact. 2. Pharmacokinetic studies conducted in conjunction with pharmacology screening can provide additional information to...

Intuitive design. Artificial intelligence helps a drugmaker learn what works.

Scientific American

Erickson D.
PMID: 1411460
Sci Am. 1992 Nov;267(5):124-5.

No abstract available.

Neural computing in cancer drug development: predicting mechanism of action.

Science (New York, N.Y.)

Weinstein JN, Kohn KW, Grever MR, Viswanadhan VN, Rubinstein LV, Monks AP, Scudiero DA, Welch L, Koutsoukos AD, Chiausa AJ.
PMID: 1411538
Science. 1992 Oct 16;258(5081):447-51. doi: 10.1126/science.1411538.

Described here are neural networks capable of predicting a drug's mechanism of action from its pattern of activity against a panel of 60 malignant cell lines in the National Cancer Institute's drug screening program. Given six possible classes of...

Catabolism of rat growth hormone-releasing factor(1-29) amide in rat serum and liver.


Boulanger L, Roughly P, Gaudreau P.
PMID: 1437711
Peptides. 1992 Jul-Aug;13(4):681-9. doi: 10.1016/0196-9781(92)90173-z.

Clinical and veterinary uses of growth hormone-releasing factor [GRF(1- 29)NH2] require the design of analogs that are resistant to proteolysis by serum and liver degrading enzymes. This study investigated rat GRF(1-29)NH2 processing in serum and liver homogenate by means...

NMR methods for elucidating macromolecule-ligand interactions: an approach to drug design. Proceedings of the Fourth Biochemical Pharmacology Symposium. New Haven, CT, 27-29 July 1989.

Biochemical pharmacology

[No authors listed]
PMID: 2372301
Biochem Pharmacol. 1990 Jul 01;40(1):1-175.

No abstract available.

Computer-assisted structure-activity correlations of dideoxynucleoside analogs as potential anti-HIV drugs.

Antiviral research

Nasr M, Litterst C, McGowan J.
PMID: 2080869
Antiviral Res. 1990 Sep;14(3):125-48. doi: 10.1016/0166-3542(90)90030-b.

No abstract available.

Showing 1 to 12 of 58347 entries